Teriparatide vs BNP (B-type Natriuretic Peptide)

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Teriparatide

Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.

Full details →

BNP (B-type Natriuretic Peptide)

BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.

Full details →

Side-by-Side Comparison

AspectTeriparatideBNP (B-type Natriuretic Peptide)
MechanismIntermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone.Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress.
Typical Dosage20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies.Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure.
AdministrationSubcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk.Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically.
Side EffectsOrthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible.Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients.
Best For

What They Have in Common

Both Teriparatide and BNP (B-type Natriuretic Peptide) are commonly used for:

Ready to Learn More?